Published in Cancer Weekly, January 11th, 2000
Adjuvant therapy is often beneficial after primary tumor resection in many types of cancer. Unfortunately, current adjuvant therapies applied to prostate cancer offer little or no advantage. Research has suggested, however, that adjuvant immunotherapy may have the potential to be beneficial in this disease.
In order to test adjuvant immunotherapies, a predictable and reliable animal model is needed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.